Payment overview · 2025
General Payments
$1,195.72
43 reported records · 12 companies
Healthcare provider profile · identity verified
Lynne Hung, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · MISSION VIEJO, CA · NPI 1326004748
Verified facts
What the public records show
CMS Open Payments records show Lynne Hung, MD received $1,195.72 in general payments during 2025 across 43 reported records.
Boston Scientific Corporation accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1210 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1210 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $477.93 | 40.0% | 17 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $195.96 | 16.4% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $123.67 | 10.3% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $102.62 | 8.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.35 | 8.1% | 6 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $65.47 | 5.5% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $35.77 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.22 | 2.1% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $24.35 | 2.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $22.55 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.08 | 1.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $5.75 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,195.72 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $199.97 | 11 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $195.96 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $135.23 | 5 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $83.61 | 2 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $74.84 | 2 | 2025 |
Source payment records
|
|||||
| OCTARAY MAPPING CATHETER Normalized: octaray mapping catheter |
Device | Biosense Webster, Inc. | $72.16 | 3 | 2025 |
Source payment records
|
|||||
| Soundstar Normalized: soundstar |
Device | Biosense Webster, Inc. | $51.51 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $50.48 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $48.63 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.51 | 3 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $35.77 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $33.98 | 1 | 2025 |
Source payment records
|
|||||
| S-ICD System Magnet Normalized: s icd system magnet |
Device | Boston Scientific Corporation | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $27.85 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| General - CRM_CRM Normalized: general crm crm |
Device | Boston Scientific Corporation | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| myLUX Patient Kit with mobile device Normalized: mylux patient kit with mobile device |
Device | Boston Scientific Corporation | $13.24 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $8.90 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $5.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1210 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1210 | 310 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1210 | 310 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 1210 | 310 |
| Xarelto | Rivaroxaban | 1119 | 285 |
| Amiodarone Hcl | Amiodarone Hcl | 669 | 218 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 101 |
| Flecainide Acetate | Flecainide Acetate | 323 | 95 |
| Sotalol | Sotalol Hcl | 269 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 268 | 94 |
| Losartan Potassium | Losartan Potassium | 263 | 84 |
| Atenolol | Atenolol | 194 | 59 |
| Furosemide | Furosemide | 170 | 61 |
| Carvedilol | Carvedilol | 162 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 50 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 141 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 112 | 35 |
| Lisinopril | Lisinopril | 100 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 87 | 26 |
| Potassium Chloride | Potassium Chloride | 87 | 33 |
| Cefadroxil | Cefadroxil | 84 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 35 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 79 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 65 | 31 |
| Benazepril Hcl | Benazepril Hcl | 64 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 18 |
| Dofetilide | Dofetilide | 47 | suppressed |
| Multaq | Dronedarone Hcl | 42 | 18 |
| Midodrine Hcl | Midodrine Hcl | 40 | 15 |
| Dilt-Xr | Diltiazem Hcl | 39 | 14 |
| Digoxin | Digoxin | 37 | 15 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 36 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | 12 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Matzim La | Diltiazem Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Disopyramide Phosphate | Disopyramide Phosphate | 13 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 13 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,195.72 · 43 records | Boston Scientific Corporation | AFFERA MAPPING SYSTEM, AVVIGO Guidance System, BIOMONITOR, Barostim Neo System, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, FARAPULSE, General - Brady, General - CRM_CRM, General - Therapies, KENGREAL, LUX-Dx Insertable Cardiac Monitor, LifeVest, NURTEC ODT, OCTARAY MAPPING CATHETER, PERCLOSE PROSTYLE, ROTAPRO, S-ICD System Magnet, Soundstar, WATCHMAN FLX, myLUX Patient Kit with mobile device | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error